Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.004
Sell
RSI(14)
39.992
Neutral
STOCH(KDJ)(9,3,3)
28.125
Neutral
ATR(14)
0.024
Low Volatility
CCI(14)
-97.499
Neutral
Williams %R
78.552
Sell
TRIX(12,20)
-0.328
Sell
StochRSI(14)
47.151
Neutral
Search
Ensysce Biosciences Inc
ENSCAdd to Watchlist
0.260USD
+0.003+0.97%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.41MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.97%
5 Days
-0.73%
1 Month
-10.52%
6 Months
-64.27%
Year to Date
-71.79%
1 Year
-87.58%
Key Figures
0.251Open
0.260High
278.51KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
3.00%Turnover Ratio
0.257Prev. Close
0.247Low
53.58KTurnover
LossP/E Static
-7.08P/B
0.00%Div Yield TTM
-347.72%ROA
2.75052wk High
1.13Volume Ratio
-7.99MNet Profit
9.28MShares
-3.1104EPS TTM
0.86Beta
-870.19%ROE
0.23052wk Low
4.98%Amplitude
100.00%Gross Margin
2.41MMarket Cap
-1.56Reward/Risk
6.08%Risk Rate
TradingKey Stock Score of Ensysce Biosciences Inc
Currency: USD Updated: 2026-07-31Key Insights
Ensysce Biosciences Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 198 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 16.45.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ensysce Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Ensysce Biosciences Inc Highlights
StrengthsRisks
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 127.15% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.07M.
Overvalued
The company’s latest PE is -0.08, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 494.53K shares, decreasing 27.86% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
16.450
Target Price
+6407.12%
Upside Space
Ensysce Biosciences Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
0
analysts
--
Current Rating
16.450
Target Price
+6407.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Ensysce Biosciences Inc
ENSC
0
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.255
Buy
MA10
0.265
Sell
MA20
0.273
Sell
MA50
0.278
Sell
MA100
0.368
Sell
MA200
0.821
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ensysce Biosciences Inc Info
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Ticker SymbolENSC
CompanyEnsysce Biosciences Inc
CEOKirkpatrick (Lynn D)
Websitehttps://ensysce.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Ensysce Biosciences Inc (ENSC)?
The current price of Ensysce Biosciences Inc (ENSC) is 0.26.
What is the symbol of Ensysce Biosciences Inc?
The ticker symbol of Ensysce Biosciences Inc is ENSC.
What is the 52-week high of Ensysce Biosciences Inc?
The 52-week high of Ensysce Biosciences Inc is 2.75.
What is the 52-week low of Ensysce Biosciences Inc?
The 52-week low of Ensysce Biosciences Inc is 0.23.
What is the market capitalization of Ensysce Biosciences Inc?
The market capitalization of Ensysce Biosciences Inc is 2.41M.
What is the Earnings Per Share (EPS TTM) of Ensysce Biosciences Inc (ENSC)?
The Earnings Per Share (EPS TTM) of Ensysce Biosciences Inc (ENSC) is -3.98.